Healthcare Business Roundup: Gilead Falls On Rivals’ Success, Neuralstem’s Positive Results
Both Bristol-Myers Squibb Company (NYSE:BMY) and Abbott Laboratories (NYSE:ABT) reported favorable study results for their HCV drugs, which caused shares of Gilead Sciences (NASDAQ:GILD) to move down modestly. However, Deutsche Bank defends the stock, asserting that the results of these studies indicate that employing different drug combinations yields more effective HCV treatments, so the data actually bode well for GILD’s 7977-based class combos, and similar results are expected.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Shares of Neuralstem (AMEX:CUR) jump, on the word of positive results for its NSI-566 study, which is a spinal cord-derived neural stem cell line tested in a rat model of ischemic stroke. The data indicated significant improvement in both motor and neurological tests, while the rats treated with the highest dose exhibiting the most significant improvement in each category.